Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Assets Average (2017 - 2026)

Ovid Therapeutics filings provide 10 years of Assets Average readings, the most recent being $188.3 million for Q1 2026.

  • Quarterly Assets Average rose 116.64% to $188.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $188.3 million through Mar 2026, up 116.64% year-over-year, with the annual reading at $121.6 million for FY2025, 2.92% up from the prior year.
  • Assets Average hit $188.3 million in Q1 2026 for Ovid Therapeutics, up from $107.4 million in the prior quarter.
  • Across five years, Assets Average topped out at $192.8 million in Q1 2022 and bottomed at $70.6 million in Q3 2025.
  • Average Assets Average over 5 years is $133.3 million, with a median of $134.5 million recorded in 2023.
  • The largest annual shift saw Assets Average plummeted 36.94% in 2025 before it surged 116.64% in 2026.
  • Ovid Therapeutics' Assets Average stood at $160.1 million in 2022, then decreased by 16.0% to $134.5 million in 2023, then fell by 27.59% to $97.4 million in 2024, then increased by 10.25% to $107.4 million in 2025, then skyrocketed by 75.32% to $188.3 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Assets Average are $188.3 million (Q1 2026), $107.4 million (Q4 2025), and $70.6 million (Q3 2025).